An official American thoracic society research statement

Current challenges facing research and therapeutic advances in airway remodeling

ATS Assembly on Respiratory Structure and Function

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Background: Airway remodeling (AR) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by current treatments. The goals of this Official American Thoracic Society (ATS) Research Statement are to discuss the scientific, technological, economic, and regulatory issues that deter progress of AR research and development of therapeutics targeting AR and to propose approaches and solutions to these specific problems. This Statement is not intended to provide clinical practice recommendations on any disease in which AR is observed and/or plays a role. Methods: An international multidisciplinary group from within academia, industry, and the National Institutes of Health, with expertise in multimodal approaches to the study of airway structure and function, pulmonary research and clinical practice in obstructive lung disease, and drug discovery platforms was invited to participate in one internet-based and one face-to-face meeting to address the above-stated goals. Although the majority of the analysis related to AR was in asthma, AR in other diseases was also discussed and considered in the recommendations. A literature search of PubMed was performed to support conclusions. The search was not a systematic review of the evidence. Results: Multiple conceptual, logistical, economic, and regulatory deterrents were identified that limit the performance of AR research and impede accelerated, intensive development of AR-focused therapeutics. Complementary solutions that leverage expertise of academia and industry were proposed to address them. Conclusions: To date, numerous factors related to the intrinsic difficulty in performing AR research, and economic forces that are disincentives for the pursuit of AR treatments, have thwarted the ability to understandARpathology and mechanisms and to address it clinically. This ATS Research Statement identifies potential solutions for each of these factors and emphasizes the importance of educating the global research community as to the extent of the problem as a critical first step in developing effective strategies for: (1) increasing the extent and impact of AR research and (2) developing, testing, and ultimately improving drugs targeting AR.

Original languageEnglish (US)
Pages (from-to)e4-e19
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume195
Issue number2
DOIs
StatePublished - Jan 15 2017

Fingerprint

Therapeutic Human Experimentation
Airway Remodeling
Thorax
Research
Obstructive Lung Diseases
Economics
Industry
Asthma
Aptitude
National Institutes of Health (U.S.)
Drug Discovery
Drug Delivery Systems
PubMed
Internet
Motivation

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

An official American thoracic society research statement : Current challenges facing research and therapeutic advances in airway remodeling. / ATS Assembly on Respiratory Structure and Function.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 195, No. 2, 15.01.2017, p. e4-e19.

Research output: Contribution to journalReview article

@article{0f4308d6d6b543fb8df90ba107963931,
title = "An official American thoracic society research statement: Current challenges facing research and therapeutic advances in airway remodeling",
abstract = "Background: Airway remodeling (AR) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by current treatments. The goals of this Official American Thoracic Society (ATS) Research Statement are to discuss the scientific, technological, economic, and regulatory issues that deter progress of AR research and development of therapeutics targeting AR and to propose approaches and solutions to these specific problems. This Statement is not intended to provide clinical practice recommendations on any disease in which AR is observed and/or plays a role. Methods: An international multidisciplinary group from within academia, industry, and the National Institutes of Health, with expertise in multimodal approaches to the study of airway structure and function, pulmonary research and clinical practice in obstructive lung disease, and drug discovery platforms was invited to participate in one internet-based and one face-to-face meeting to address the above-stated goals. Although the majority of the analysis related to AR was in asthma, AR in other diseases was also discussed and considered in the recommendations. A literature search of PubMed was performed to support conclusions. The search was not a systematic review of the evidence. Results: Multiple conceptual, logistical, economic, and regulatory deterrents were identified that limit the performance of AR research and impede accelerated, intensive development of AR-focused therapeutics. Complementary solutions that leverage expertise of academia and industry were proposed to address them. Conclusions: To date, numerous factors related to the intrinsic difficulty in performing AR research, and economic forces that are disincentives for the pursuit of AR treatments, have thwarted the ability to understandARpathology and mechanisms and to address it clinically. This ATS Research Statement identifies potential solutions for each of these factors and emphasizes the importance of educating the global research community as to the extent of the problem as a critical first step in developing effective strategies for: (1) increasing the extent and impact of AR research and (2) developing, testing, and ultimately improving drugs targeting AR.",
author = "{ATS Assembly on Respiratory Structure and Function} and Prakash, {Y. S.} and Halayko, {Andrew J.} and Reinoud Gosens and Panettieri, {Reynold A.} and Blanca Camoretti-Mercado and Penn, {Raymond B.} and Ram Aiyar and Alaina Ammit and Neville Berkman and Richard Bond and Robert Brown and Louis Boulet and Janette Burgess and Chung, {Kian Fan} and Jason Debley and Deepak Deshpande and Michelle Freemer and Mitchell Glass and Angela Haczku and Stephen Holgate and Charles Irvin and David Jacoby and Jill Johnson and Hermann Meurs and Thomas Murphy and Mahadev Murthy and Patricia Noel and Paul O'Byrne and Christina Pabelick and Tonio Pera and Matthew Poynter and Gary Robinson and Sejal Saglani and Julian Solway and Alastair Stewart and Omar Tliba and Alkis Togias and Prescott Woodruff",
year = "2017",
month = "1",
day = "15",
doi = "10.1164/rccm.201611-2248ST",
language = "English (US)",
volume = "195",
pages = "e4--e19",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - An official American thoracic society research statement

T2 - Current challenges facing research and therapeutic advances in airway remodeling

AU - ATS Assembly on Respiratory Structure and Function

AU - Prakash, Y. S.

AU - Halayko, Andrew J.

AU - Gosens, Reinoud

AU - Panettieri, Reynold A.

AU - Camoretti-Mercado, Blanca

AU - Penn, Raymond B.

AU - Aiyar, Ram

AU - Ammit, Alaina

AU - Berkman, Neville

AU - Bond, Richard

AU - Brown, Robert

AU - Boulet, Louis

AU - Burgess, Janette

AU - Chung, Kian Fan

AU - Debley, Jason

AU - Deshpande, Deepak

AU - Freemer, Michelle

AU - Glass, Mitchell

AU - Haczku, Angela

AU - Holgate, Stephen

AU - Irvin, Charles

AU - Jacoby, David

AU - Johnson, Jill

AU - Meurs, Hermann

AU - Murphy, Thomas

AU - Murthy, Mahadev

AU - Noel, Patricia

AU - O'Byrne, Paul

AU - Pabelick, Christina

AU - Pera, Tonio

AU - Poynter, Matthew

AU - Robinson, Gary

AU - Saglani, Sejal

AU - Solway, Julian

AU - Stewart, Alastair

AU - Tliba, Omar

AU - Togias, Alkis

AU - Woodruff, Prescott

PY - 2017/1/15

Y1 - 2017/1/15

N2 - Background: Airway remodeling (AR) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by current treatments. The goals of this Official American Thoracic Society (ATS) Research Statement are to discuss the scientific, technological, economic, and regulatory issues that deter progress of AR research and development of therapeutics targeting AR and to propose approaches and solutions to these specific problems. This Statement is not intended to provide clinical practice recommendations on any disease in which AR is observed and/or plays a role. Methods: An international multidisciplinary group from within academia, industry, and the National Institutes of Health, with expertise in multimodal approaches to the study of airway structure and function, pulmonary research and clinical practice in obstructive lung disease, and drug discovery platforms was invited to participate in one internet-based and one face-to-face meeting to address the above-stated goals. Although the majority of the analysis related to AR was in asthma, AR in other diseases was also discussed and considered in the recommendations. A literature search of PubMed was performed to support conclusions. The search was not a systematic review of the evidence. Results: Multiple conceptual, logistical, economic, and regulatory deterrents were identified that limit the performance of AR research and impede accelerated, intensive development of AR-focused therapeutics. Complementary solutions that leverage expertise of academia and industry were proposed to address them. Conclusions: To date, numerous factors related to the intrinsic difficulty in performing AR research, and economic forces that are disincentives for the pursuit of AR treatments, have thwarted the ability to understandARpathology and mechanisms and to address it clinically. This ATS Research Statement identifies potential solutions for each of these factors and emphasizes the importance of educating the global research community as to the extent of the problem as a critical first step in developing effective strategies for: (1) increasing the extent and impact of AR research and (2) developing, testing, and ultimately improving drugs targeting AR.

AB - Background: Airway remodeling (AR) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by current treatments. The goals of this Official American Thoracic Society (ATS) Research Statement are to discuss the scientific, technological, economic, and regulatory issues that deter progress of AR research and development of therapeutics targeting AR and to propose approaches and solutions to these specific problems. This Statement is not intended to provide clinical practice recommendations on any disease in which AR is observed and/or plays a role. Methods: An international multidisciplinary group from within academia, industry, and the National Institutes of Health, with expertise in multimodal approaches to the study of airway structure and function, pulmonary research and clinical practice in obstructive lung disease, and drug discovery platforms was invited to participate in one internet-based and one face-to-face meeting to address the above-stated goals. Although the majority of the analysis related to AR was in asthma, AR in other diseases was also discussed and considered in the recommendations. A literature search of PubMed was performed to support conclusions. The search was not a systematic review of the evidence. Results: Multiple conceptual, logistical, economic, and regulatory deterrents were identified that limit the performance of AR research and impede accelerated, intensive development of AR-focused therapeutics. Complementary solutions that leverage expertise of academia and industry were proposed to address them. Conclusions: To date, numerous factors related to the intrinsic difficulty in performing AR research, and economic forces that are disincentives for the pursuit of AR treatments, have thwarted the ability to understandARpathology and mechanisms and to address it clinically. This ATS Research Statement identifies potential solutions for each of these factors and emphasizes the importance of educating the global research community as to the extent of the problem as a critical first step in developing effective strategies for: (1) increasing the extent and impact of AR research and (2) developing, testing, and ultimately improving drugs targeting AR.

UR - http://www.scopus.com/inward/record.url?scp=85009787260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009787260&partnerID=8YFLogxK

U2 - 10.1164/rccm.201611-2248ST

DO - 10.1164/rccm.201611-2248ST

M3 - Review article

VL - 195

SP - e4-e19

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -